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Abstract
Background: Two important regulators for circulating lipid metabolisms are lipoprotein lipase (LPL) and hepatic
triglyceride lipase (HTGL). In relation to this, glycosylphosphatidylinositol anchored high-density lipoprotein binding
protein 1 (GPIHBP1) has been shown to have a vital role in LPL lipolytic processing. However, the relationships
between skeletal muscle mass and lipid metabolism, including LPL, GPIHBP1, and HTGL, remain to be elucidated.
Demonstration of these relationships may lead to clarification of the metabolic dysfunctions caused by sarcopenia.
In this study, these relationships were investigated in young Japanese men who had no age-related factors;
participants included wrestling athletes with abundant skeletal muscle.
Methods: A total of 111 young Japanese men who were not taking medications were enrolled; 70 wrestling
athletes and 41 control students were included. The participants’ body compositions, serum concentrations of
lipoprotein, LPL, GPIHBP1 and HTGL and thyroid function test results were determined under conditions of no
extreme dietary restrictions and exercises.
Results: Compared with the control participants, wrestling athletes had significantly higher skeletal muscle index
(SMI) (p < 0.001), higher serum concentrations of LPL (p < 0.001) and GPIHBP1 (p < 0.001), and lower fat mass index
(p = 0.024). Kruskal–Wallis tests with Bonferroni multiple comparison tests showed that serum LPL and GPIHBP1
concentrations were significantly higher in the participants with higher SMI. Spearman’s correlation analyses showed
that SMI was positively correlated with LPL (ρ = 0.341, p < 0.001) and GPIHBP1 (ρ = 0.309, p = 0.001) concentration. The
serum concentrations of LPL and GPIHBP1 were also inversely correlated with serum concentrations of triglyceride
(LPL, ρ = − 0.198, p = 0.037; GPIHBP1, ρ = − 0.249, p = 0.008). Serum HTGL concentration was positively correlated with
serum concentrations of total cholesterol (ρ = 0.308, p = 0.001), low-density lipoprotein-cholesterol (ρ = 0.336, p < 0.001),
and free 3,5,3′-triiodothyronine (ρ = 0.260, p = 0.006), but not with SMI.
Conclusions: The results suggest that increased skeletal muscle mass leads to improvements in energy metabolism by
promoting triglyceride-rich lipoprotein hydrolysis through the increase in circulating LPL and GPIHBP1.
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Background
The skeletal muscle is a major organ involved in sys-
temic energy metabolism. As the population is aging
rapidly, the increase in the number of patients with
decreased skeletal muscle mass, called sarcopenia, is
becoming an evident clinical problem. It is known that
sarcopenia is associated with cardiovascular diseases and
metabolic disorders, including dyslipidemia [1–5]; how-
ever, the detailed mechanism of metabolic dysfunction
by sarcopenia remains to be clarified. It is believed that
one way to prevent metabolic diseases is to maintain an
appropriate amount of skeletal muscle through physical
activities, such as exercise. However, there have been
few reports on the effects of increasing skeletal muscle
mass on lipid metabolism.
Two key enzymes involved in circulating lipid metab-
olism are lipoprotein lipase (LPL) and hepatic triglycer-
ide lipase (HTGL) [6–9]. LPL has a major role in
triglyceride (TG)-rich lipoprotein metabolism by catalyz-
ing the hydrolysis of TG in chylomicrons and very
low-density lipoproteins to form chylomicron and very
low-density lipoprotein remnants, respectively [6, 7].
LPL is expressed and synthesized mainly in adipose and
skeletal muscle tissue that store and consume fatty acids,
respectively, and is translocated to the capillary lumen
by glycosylphosphatidylinositol anchored high-density
lipoprotein (HDL) binding protein 1 (GPIHBP1) [8].
GPIHBP1 anchors the LPL on the surface of capillary
endothelial cells and has a crucial role in the lipolytic
processing of TG-rich lipoproteins by LPL [7, 8]. Recent
reports have demonstrated that GPIHBP1 autoantibodies
and gene mutations cause hypertriglyceridemia [10–16].
Regarding HTGL, it has been known that it has a role in
catalyzing the hydrolysis of the smaller remnants into
low-density lipoprotein (LDL) and has a primary role in
HDL metabolism [9, 17]. HTGL is synthesized in the
liver and bound to heparin sulfate proteoglycans on
surfaces of the liver sinusoidal capillaries [9, 17].
Thyroid hormone has a crucial role in lipid metabol-
ism [18]. Higher levels of serum remnant-like particle
cholesterol (RLP-C), which is the atherogenic lipopro-
tein, have been found in patients with hypothyroidism
and subclinical hypothyroidism compared with matched
controls, and their RLP-C concentrations were decreased
after levothyroxine therapy [19, 20]. There have been
reports that levothyroxine therapy increases plasma LPL
[19] and HTGL [19, 20] activities. However, the correla-
tions between serum free thyroid hormone concentra-
tions and LPL, HTGL, and GPIHBP1 concentrations
have not been fully elucidated.
Extensive studies on the tissue-specific activities of
lipases in animal models and circulating activities and
concentrations of lipases in plasma have been conducted
to clarify the biological functions of LPL and HTGL [6, 7].
Studies were conducted to specially investigate LPL’s asso-
ciation with exercise because of expression in skeletal
muscle. Previous reports have proven that regular exercise
lowers serum TG concentrations through increases in
muscle and serum LPL activities [7, 21]. In contrast, it has
been shown that decreased serum LPL concentrations are
associated with metabolic syndrome, diabetes, and coron-
ary atherosclerosis [22–26]. In the case of HTGL, al-
though its pathophysiologic role has been investigated
mainly in terms of association with atherosclerosis, by
measurement of circulating HTGL activities, studies have
indicated contradictory results regarding associations with
atherosclerosis [27–31]. In the past, owing to the low sen-
sitivities of assays, previous methods used for measuring
circulating activities and concentrations of lipases required
heparin administration. Therefore, assay methods based
on the monoclonal antibodies against these lipases have
been developed recently to achieve sufficient sensitivities
for measurement of serum LPL and HTGL concentrations
without the need for heparin administration [32–34]. As a
result, preheparin serum LPL concentrations can now be
measured using a latex particle-enhanced turbidimetric
immunoassay with an automated analyzer [35], and prehe-
parin serum HTGL concentrations can be determined
using high-sensitivity HTGL enzyme-linked immunosorb-
ent assay (ELISA) [34]. Furthermore, ELISA methods have
been developed recently for the measurement of serum
concentrations of GPIHBP1 [36].
These methods were used in two recent studies to
demonstrate the clinical relevance of preheparin serum
concentrations of LPL and HTGL and serum concentra-
tions of GPIHBP1. The first study reported that in
patients with coronary artery disease, increases in
atherogenic lipoproteins, such as RLP-C, were associated
with an increase in preheparin serum HTGL concentra-
tion and a decrease in preheparin serum LPL concentra-
tion [37]. The second study demonstrated that in obese
middle-aged women, a diet and exercise intervention
contributed to increased serum GPIHBP1 concentration,
but not LPL concentrations, in association with a de-
crease in body weight and body fat [38]. However, these
two studies found that multiple factors influenced lipid
metabolism because most participants were older people
who had arteriosclerosis or metabolic disorders and
took medication, including statins. Furthermore, the
relationship between skeletal muscle mass and lipid
metabolism, including LPL, GPIHBP1, and HTGL, re-
mains to be elucidated. One effective way to clarify
these relationships is to conduct an investigation on
young individuals with abundant skeletal muscle who
do not have age-related factors. In addition, presenta-
tion of these relationships may lead to a clarification
of the mechanisms involved in metabolic dysfunctions
caused by sarcopenia.
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In this study, the aims were to analyze the characteris-
tics of body composition and serum lipid metabolism
and investigate the association between skeletal muscle
mass and serum concentrations of LPL, GPIHBP1, and
HTGL in young Japanese men, which included skeletal
muscle-rich wrestling athletes, who did not have meta-
bolic disorders or arteriosclerosis.
Materials and methods
Participants
Participants in this cross-sectional study included 111
young, healthy Japanese men who were not taking medi-
cations for metabolic diseases. Seventy were amateur
wrestlers (age range, 16–26 years) and 41 were college
students who did not engage in habitual hard exercise
(age range, 18–24 years). In general, wrestling athletes
begin to decrease their food intake for weight loss and
to exercise hard at approximately 2 weeks before a
wrestling tournament with weight categories [39]. In this
study, wrestling athletes’ body compositions, serum
lipoproteins, lipases, and lipase-associated protein were
determined during periods wherein they were not under
dietary restrictions or were not undergoing hard prac-
tices for a tournament.
Participants provided written informed consent before
being included in the study. The ethics committee of
Gunma University Graduate School of Medicine ap-
proved this study (approval no. 13–36).
Physical examinations
Physical examinations and blood sample collections were
performed in the morning after a 12-h fast. A bioimpe-
dance instrument (InBody 430; InBody Japan, Tokyo,
Japan) was used to measure body weight, fat mass, and
skeletal muscle mass, with the participant in the stand-
ing position. Body mass index (BMI), fat mass index
(FMI), and skeletal muscle index (SMI) were calculated
respectively as follows: weight/height squared (kg/m2),
fat mass/height squared (kg/m2), and skeletal muscle
mass/height squared (kg/m2).
Measurement of thyroid function and serum
concentrations of lipoprotein, lipases, and lipase-
associated protein
With the participants sitting down, blood samples were
collected after an antecubital vein is punctured using
23-G needles. Serum samples were separated by centri-
fugation (1500×g) at 4 °C for 10 min and were stored at
− 80 °C until analysis. A chemiluminescent microparticle
immunoassay on an Abbott ARCHITECT i2000SR Im-
munoassay Analyzer (Abbott Laboratories, Abbott Park,
Illinois) was used to analyze the serum concentrations of
free 3,5,3′-triiodothyronine (FT3), free thyroxine (FT4),
and thyrotropin (TSH). Enzymatic methods using a
LABOSPECT 008 automatic analyzer (Hitachi, Tokyo,
Japan) were carried out to measure serum total choles-
terol (TC), HDL cholesterol (HDL-C), and TG concen-
trations. The Friedewald formula was used to determine
LDL cholesterol (LDL-C) concentrations: LDL-C = TC −
HDL-C −TG/5 [40].
LPL latex agglutination turbidimetry (Immuno-Biolo-
gical Laboratories [IBL], Gunma, Japan) was used to
measure serum LPL concentrations [35]. A Human
GPIHBP1 Assay Kit (IBL) based on sandwich ELISA was
used to determine serum GPIHBP1 concentrations [36].
Finally, the Human Serum HTGL ELISA Kit (IBL) was
used to measure serum HTGL concentrations [34].
Statistical analysis
Because almost all variables were not normally distributed,
data are expressed as median values with a 25th–75th per-
centile range, rather than as mean values with standard
deviations. Unpaired Student’s t tests or Mann–Whitney
U tests were used, as appropriate, to identify statistically
significant differences between the two study groups.
Kruskal–Wallis tests with Bonferroni multiple comparison
tests were performed to compare the two groups classified
by quartile. Spearman’s correlation analyses were carried
out to determine the relationships between serum concen-
trations of LPL, GPIHBP1, or HTGL and the clinical
parameters. Differences and correlations were considered
significant when p < 0.05. SPSS Statistics version 25.0
(SPSS, Inc., Chicago, Illinois) was used to perform all
statistical analyses.
Results
Clinical characteristics in control and wrestling athlete
participants
The 111 young Japanese men were divided into two
groups: control participants (n = 41), who did not engage
in habitual hard exercise, and wrestling athletes (n = 70).
Table 1 shows the results of the physical examinations
and lipid metabolism analyses in the two groups.
Compared with participants in the control group, partic-
ipants in the athlete group had significantly higher
weights (p = 0.012), BMI (p < 0.001), and SMI (p < 0.001)
and lower FMI (p = 0.024). Similarly, lipid metabolism
analyses showed that the athlete group participants had
significantly higher serum concentrations of HDL-C (p
= 0.016), LPL (p < 0.001), and GPIHBP1 (p < 0.001).
Serum concentrations of TG tended to be lower in ath-
letes, although the differences between the two groups
were not statistically significant (p = 0.288). There were
no differences in serum HTGL concentrations and thy-
roid function tests between the groups. Results of the
thyroid function tests showed values that were within
reference range in all participants.
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Association between SMI and serum concentrations of
LPL, GPIHBP1, and HTGL
Figure 1 shows the associations between SMI and serum
concentrations of LPL, GPIHBP1, and HTGL in all par-
ticipants. Figure 1a shows the comparison of serum con-
centrations of LPL, GPIHBP1, and HTGL between the
SMI groups classified by quartile. The SMI values of
each group are as follows: group 1, SMI ≤ 11.0; group 2,
11.0 < SMI ≤ 11.9; group 3, 11.9 < SMI ≤ 12.5; and group
4, 12.5 < SMI. Kruskal–Wallis tests indicate that there
were significant differences among the SMI groups in
serum concentrations of LPL (p < 0.001) and GPIHBP1
(p = 0.011). Moreover, Bonferroni multiple comparison
tests show that the serum concentrations of LPL in
groups 3 and 4 were significantly higher than that in
group 1, and serum concentrations of GPIHBP1 in
group 4 were significantly higher than that in group 1.
There was no significant difference in serum HTGL con-
centrations among the SMI groups. In addition, results
of the Spearman’s correlation analyses show that SMI
was positively correlated with LPL (ρ = 0.341, p < 0.001)
and GPIHBP1 (ρ = 0.309, p = 0.001) concentration but
was not correlated with HTGL concentration (ρ = −
0.013, p = 0.891) (Fig. 1b). Weight-adjusted skeletal
muscle mass, calculated as skeletal muscle mass/weight,
was also correlated with LPL (ρ = 0.364, p < 0.001) and
GPIHBP1 (ρ = 0.206, p = 0.022) concentration (data not
shown).
Correlation between LPL and GPIHBP1 concentrations
and clinical variables
Figure 2a shows the results of the Spearman’s correlation
analyses between GPIHBP1 and LPL or HTGL concen-
trations in all participants. Results indicate that LPL
concentration was positively correlated with GPIHBP1
concentration (ρ = 0.251, p = 0.008). In contrast, HTGL
concentration was not correlated with GPIHBP1 con-
centrations (ρ = 0.057, p = 0.553). Table 2 shows the cor-
relation between serum concentrations of LPL and
GPIHBP1 and other clinical variables in all participants.
LPL concentration were positively correlated with SMI
and HDL-C (ρ = 0.389, p < 0.001) and inversely correlated
with FMI (ρ = − 0.222, p = 0.019) and TG (ρ = − 0.198, p =
0.037; Fig. 2b). Moreover, GPIHBP1 concentrations were
positively correlated with SMI and inversely correlated
with TG (ρ = − 0.249, p = 0.008; Fig. 2b). LPL and
GPIHBP1 concentrations were not correlated with results
of the thyroid function tests.
Correlation between HTGL concentrations and clinical
variables
Table 2 and Fig. 3 show the results of the Spearman’s
correlation analyses between HTGL concentrations and
other clinical variables in all participants. HTGL concen-
tration was positively correlated with TC (ρ = 0.308, p =
0.001), LPL-C (ρ = 0.336, p < 0.001), and FT3 (ρ = 0.260,
p = 0.006) concentrations but was not correlated with
Table 1 Clinical Characteristics in Control and Wrestling Athlete Participants
All Participants Control Participants Athletes p
(n = 111) (n = 41) (n = 70)
Age (years) 20 (19.0–21.0) 19 (18.0–20.0) 20 (19.0–21.0) 0.001
Weight (kg) 66.6 (62.3–74.2) 64.2 (58.1–68.4) 68.4 (63.6–75.9) 0.012
BMI (kg/m2) 23.7 (22.2–25.6) 21.7 (20.1–24.0) 24.2 (23.2–26.0) < 0.001
FMI (kg/m2) 2.7 (2.3–3.7) 3.2 (2.3–4.9) 2.6 (2.2–3.5) 0.024
SMI (kg/m2) 11.9 (11.0–12.5) 10.5 (9.9–11.5) 12.4 (11.9–13.0) < 0.001
TC (mg/dL) 168 (150–186) 171 (156–186) 167 (145–186) 0.452
LDL-C (mg/dL) 94 (83–110) 100 (85–115) 93 (82–105) 0.282
HDL-C (mg/dL) 56 (51–66) 53 (48–63) 59 (53–67) 0.016
TG (mg/dL) 64 (49–81) 66 (49–101) 64 (49–76) 0.288
LPL (ng/mL) 62.5 (52.5–72.6) 52.3 (47.6–59.0) 67.3 (60.2–76.0) < 0.001
GPIHBP1 (pg/mL) 986 (853–1150) 934 (742–1039) 1038 (890–1283) < 0.001
HTGL (ng/mL) 44.1 (33.1–61.1) 43.9 (34.6–61.3) 45.5 (30.0–61.0) 0.525
FT3 (pg/mL) 3.22 (3.09–3.39) 3.18 (3.04–3.34) 3.23 (3.10–3.41) 0.115
FT4 (ng/dL) 1.04 (0.98–1.10) 1.02 (0.98–1.10) 1.05 (0.97–1.11) 0.318
TSH (μIU/mL) 1.78 (1.24–2.25) 1.84 (1.19–2.12) 1.67 (1.36–2.30) 0.647
Data are expressed as median (25th–75th percentile)
Wrestling athletes were compared with control participants using the unpaired Student’s t test or Mann-Whitney U test as appropriate
BMI body mass index, FMI fat mass index, SMI skeletal muscle index, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein
cholesterol, TG triglyceride, LPL lipoprotein lipase, GPIHBP1 glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1, HTGL hepatic
triglyceride lipase, FT3 free 3,5,3′-triiodothyronine, FT4 free thyroxine, TSH thyrotropin
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FT4 and TSH concentrations. FT3, FT4, and TSH concen-
trations were not correlated with any data from the phys-
ical examination or lipoprotein analyses (data not shown).
Discussion
The analyses in this study show the associations between
skeletal muscle mass and lipid metabolism, including
LPL, GPIHBP1, and HTGL, in young Japanese men.
Significantly high serum concentrations of preheparin
LPL and GPIHBP1 were found in wrestling athletes with
abundant skeletal muscle mass. Participants with higher
SMI showed significantly higher serum concentrations
of LPL and GPIHBP1. Moreover, in all participants,
serum concentrations of LPL and GPIHBP1 correlated
positively with SMI and inversely with TG concentra-
tions. Serum HTGL concentration was positively corre-
lated with TC, LDL-C, and FT3 concentrations but not
was correlated with skeletal muscle mass.
Previous studies have shown that preheparin serum
LPL concentrations were positively correlated with
HDL-C concentration and inversely correlated with TG
concentration [22, 37, 41–43]. In addition, it has been
reported that LPL concentration is inversely correlated
with intra-abdominal visceral fat accumulation, as evalu-
ated by computed tomography [22], and with the num-
ber of metabolic syndrome symptoms [23]. In agreement
with these studies, we observed correlations of LPL with
lipoprotein concentrations and FMI. Some studies have
identified several GPIHBP1 gene missense mutations
that cause chylomicronemia [8, 10–15]. These mutations
block the ability of GPIHBP1 to bind LPL and shuttle it
to the capillary lumen owing to the disruption to fold
the lymphocyte antigen 6/urokinase-type plasminogen
activator receptor domain that binds LPL with high
affinity [10–15]. In addition, recent reports have identi-
fied the presence of GPIHBP1 antibodies that inhibit the
ability of GPIHBP1 to bind and transport LPL in pa-
tients with hypertriglyceridemia [16]. The positive cor-
relation between GPIHBP1 and TG concentrations in
this study agrees with the relevance reported in these
previous studies. In addition, in agreement with a previ-
ous study [37], there was a positive correlation between
GPIHBP1 concentration and LPL concentration, but
there was no correlation between GPIHBP1 concentra-
tion and HTGL concentration. On one hand, several
studies on humans have revealed that physical exercise
leads to an increase in LPL activity and mRNA in the
exercising muscle [44–48] and to an increase in posthe-
parin plasma LPL activity and preheparin serum LPL
concentration [49, 50]. On the other hand, one study
[38] reported an association between GPIHBP1 concen-
tration and physical exercise, wherein reduction in
A
B
Fig. 1 Association between SMI and serum concentrations of LPL, GPIHBP1, and HTGL (n = 111 men). a Serum LPL, GPIHBP1, and HTGL
concentrations between the two groups, classified by SMI quartile (group 1, SMI≤ 11.0; group 2, 11.0 < SMI ≤ 11.9; group 3, 11.9 < SMI≤ 12.5;
group 4, 12.5 < SMI). Kruskal–Wallis tests with Bonferroni multiple comparison tests were used to compare the two groups (*p < 0.05, ** p < 0.01).
b Results of the Spearman’s correlation analyses between SMI and serum concentrations of LPL, GPIHBP1, and HTGL
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weight as a result of a diet and exercise intervention in-
creased serum GPIHBP1 concentration, but not serum
LPL concentration, in Japanese women who were obese.
However, the relationship between LPL and GPIHBP1
and skeletal muscle mass, including sarcopenia, has not
been fully understood. In this study, there were signifi-
cantly higher LPL and GPIHBP1 concentrations in
wrestling athletes than in control participants. This
difference may be affected not only by the quantity but
also the quality of athletes’ muscle with continuing ha-
bitual trainings, but the multiple comparison analysis
and the correlation analysis among all participants, in-
cluding controls, also indicated that the participants with
higher SMI had higher LPL and GPIHBP1 concentra-
tions as well. To our knowledge, this is the first study to
report on the relevance of the relationship between skel-
etal muscle mass and serum concentration of GPIHBP1,
as well as serum concentrations of LPL. The results of
this study suggest that increased skeletal muscle mass
results in effective energy use through the promotion of
TG-rich lipoprotein hydrolysis through elevation of
serum LPL and GPIHBP1 concentrations. Conversely,
unlike LPL, GPIHBP1 concentration was not correlated
Table 2 Spearman’s correlation analyses between LPL, GPIHBP1,
and HTGL concentrations and clinical variables in 111
participants
LPL GPIHBP1 HTGL
Variable (n = 111) ρ p ρ p ρ ρ
Age (years) 0.053 0.577 −0.059 0.542 0.065 0.501
Weight (kg) 0.075 0.432 0.153 0.109 0.065 0.496
BMI (kg/m2) 0.123 0.199 0.167 0.081 0.087 0.361
FMI (kg/m2) −0.222 0.019 −0.143 0.135 0.112 0.210
SMI (kg/m2) 0.341 < 0.001 0.309 0.001 −0.013 0.891
TC (mg/dL) −0.003 0.976 −0.167 0.080 0.308 0.001
LDL-C (mg/dL) −0.079 0.413 −0.064 0.504 0.336 < 0.001
HDL-C (mg/dL) 0.389 < 0.001 0.003 0.974 −0.092 0.337
TG (mg/dL) −0.198 0.037 −0.249 0.008 0.057 0.551
FT3 (pg/mL) 0.161 0.092 0.017 0.862 0.260 0.006
FT4 (ng/dL) 0.139 0.146 0.086 0.371 0.035 0.712
TSH (μIU/mL) 0.121 0.204 0.003 0.971 −0.041 0.669
A
B
Fig. 2 Correlations between serum LPL and GPIHBP1 concentrations and clinical variables (n = 111 men). Results of the Spearman’s correlation
analyses (a) between serum GPIHBP1 concentrations and serum LPL and HTGL concentrations and (b) between serum TG concentration and
serum LPL and GPIHBP1 concentrations
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with FMI and HDL-C concentrations. Future studies are
needed to explore these distinctions in correlations
through clinical and molecular analyses and to investi-
gate the association between these proteins and the
qualities of skeletal muscle, such as slow-stich muscle
and fast-stich muscle.
The inverse relation between HTGL activities and the
buoyancies and sizes of LDL and HDL particles has been
shown in one study [9]. In addition, in the last decade, a
number of studies have reported on increases and de-
creases in HTGL activities associated with atheroscler-
osis [27–31]. In a recent study [37] using high-sensitivity
ELISA for patients with coronary artery diseases, prehe-
parin serum HTGL concentrations were positively corre-
lated with small dense LDL-C (sdLDL-C) and RLP-C
concentrations, but not with LDL-C or large-buoyant
LDL-C concentrations. However, because most partici-
pants in that study were taking statins, only the positive
correlations with sdLDL-C, which is unlikely to be af-
fected by statins, were considered. In contrast, in the
young participants in this study, age, medication use, or
anamnestic factors had no effect on lipid metabolism,
which were likely reflected by the positive correlation
between HTGL and LDL-C concentrations. Moreover,
in this study, there were no differences in serum HTGL
concentrations between the athletes and the control
participants, and there was no correlation between the
HTGL concentration and skeletal muscle mass. This
suggests that HTGL is produced by hepatocytes, but not
by skeletal muscle cells [9, 17].
Previous studies have demonstrated that in patients
with hypothyroidism who were treated with levothyrox-
ine, increased HTGL activities were associated with de-
creases in serum RLP-C concentration [19, 20]. Moreover,
one study [51] showed that T3 increased the posttransla-
tional HTGL expression in HepG2 cells. However, no
direct correlations between HTGL activities and thyroid
hormone concentrations were demonstrated. In this study,
there was a significant, positive correlation between FT3
and preheparin serum HTGL concentrations in young
men with euthyroid state. This correlation provides sup-
port for the relationships between HTGL activities and
thyroid hormones shown in previous molecular and
clinical studies. In this study, however, there were no cor-
relations between serum HTGL concentrations and FT4
and TSH concentrations. The differences in the correla-
tions with HTGL concentration may be attributable to
more potent physiologic activity of T3 than that of T4.
Our results suggest that HTGL seems to accelerate the
synthesis of LDL-C in proportion to serum FT3 concen-
tration. Future studies are needed to determine the de-
tailed effect of thyroid hormone on lipid metabolism,
including HTGL, in various thyroid states.
Limitations of this study should be acknowledged,
which include the cross-sectional design of the study
and the relatively small sample size. One reason for the
small sample size is that only men were enrolled in this
study. Women were not included because they have
menstrual cycles and different body compositions that
may have an effect on lipid metabolism. Although there
were no participants with sarcopenia in this study who
had skeletal muscle mass less than 20 kg and SMI less
than 7.0 kg/m2, which are cutoff points provided by the
European Working Group on Sarcopenia in Older
People 2 [52], we focused enrollment on many young
wrestling athletes with a large amount of skeletal muscle
in the same condition without extreme dietary restric-
tions and hard practices. Moreover, the control partici-
pants were significantly younger than the wrestling
athletes, but this may not have been a serious con-
founder as there was an almost unremarkable difference
between the ages of the two groups, and no participant
had age-related factors, such as medication use or meta-
bolic diseases. These assertions can also be supported by
analyses conducted for other lipid markers, such as
RLP-C and sdLDL-C. Moreover, further studies are
needed to confirm our hypothesis by evaluating more
markers of total energy metabolism in a larger cohort
Fig. 3 Correlations between serum HTGL concentrations and clinical variables (n = 111 men). Results of the Spearman’s correlation analyses
between serum HTGL concentration and TC, LDL-C, and FT3 concentration
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that includes women, elderly people, individuals with
sarcopenia, and the like.
Conclusions
In conclusion, the serum concentrations of LPL and
GPIHBP1 were significantly high in skeletal muscle-rich
participants and were positively correlated with skeletal
muscle mass in young Japanese men. These results
suggest that increases in skeletal muscle mass lead to
improvements in energy use by promoting TG-rich lipo-
protein hydrolysis through increases in circulating LPL
and GPIHBP1 concentrations. In contrast, high serum
concentration of HTGL seems to increase the synthesis
of serum LDL-C in proportion to FT3 concentration,
regardless of skeletal muscle mass.
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